Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients

Abstract

This study prospectively analysed the relationships between observed to vary according to the type and number of lymphimmunophenotypic and cytogenetic features of blast cells in oid lineage antigens expressed. 9 The expression of some of 432 acute non-lymphoblastic leukemias (ANLL) at presentation.these antigens also appeared to be related to recurrent cyto- The study was initiated in March 1992 by the Groupe d'Etude Immunologique des Leucémies (GEIL), a French multicentric Introduction group that collects data from over 40 centers in France and Belgium. The endpoint of the present analysis was 30 SepIn 1988, the morphologic, immunologic and cytogenetic tember 1994. Patients eligible for the study met the following working classification (MIC) of acute non-lymphoblastic leucriteria: established diagnosis of ANLL and collection of a sufkemia (ANLL) 1 underlined the correlations between some ficient number of blast cells for both immunophenotype and recurrent specific cytogenetic abnormalities and defined cytosuccessful cytogenetic analysis. M0-ANLL were defined as logic subgroups. At that time, the relationships between cytopreviously reported. 2 FAB data were collected from each genetic features identified in ANLL and the immunophenotype center's cytology laboratory. of blast cells remained poorly characterised. During the last 10 years, immunophenotypic analysis of ANLL blast cells has provided new information and become a powerful tool in Immunological phenotyping assigning undifferentiated acute leukaemia to the myeloid lineage. 2 Meanwhile, investigation of lymphoid lineage antigens Mononuclear cells were recovered from heparinized bone on blast cells from a large number of ANLL has demonstrated marrow (391 cases) or peripheral blood (41 cases) collected the high immunophenotypic heterogeneity of morphologically at diagnosis. The percentage of blast cells after separation on and cytogenetically well-defined diseases. [3][4][5][6][7][8] a Ficoll gradient was higher than 50% in M2 and M4 subtypes Molecular analyses attempting to correlate these immunoand higher than 80% in the remaining cases. The immunophenotypic features to their genotypic counterpart did not phenotype was performed by flow cytometry on blast cells demonstrate any strict correlation between the rearrangement gated on their abnormal light scatter characteristics, using of immunoglobulin and T cell receptor genes and the monoclonal antibodies for the following antigens: CD9 expression of lymphoid lineage antigens on ANLL blast (IOB2), CD11b (FD11), CD13 (MY7), CD14 (UCHM1), cells. 3,9-11 However, the prevalence of genotypic changes was CD15a (SMY15a), CD16 (Leu11b), CD18 (IOT18), CD33 (MY9), CD34 (BI-3C5), CD35 (44-D), CD36 (OKM5), CDw65 (VIM2), CD41 (P2), CD42 (SZ2), T lymphoid differentiation

A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China

“…Indeed, in non-M3 subtypes, 73.1% of CD34-positive patients had chromosome abnormalities. Although some reports failed to find the correlation between CD19 expression and the presence of t(8;21) in M2 cases (1), our results also further support the well-recognized knowledge that the expressions of CD15, CD19, CD34, and CD56 were significantly increased in AML with t(8;21) (9)(10)(11). Reports showed that immunophenotyping had a sensitivity of 100% and a specificity of 99% for predicting PML/RARalpha gene rearrangements, and the expression pattern of CD34, CD15, and CD13 was highly characteristic of the presence of it (2).…”

“…Previous studies suggested that several antigens such as CD34, CD56, and TdT on AML cells were highly related to abnormal chromosome karyotype, but the patients found with cytogenetic changes were mostly lacking special immunophenotypes (9,10). Our study showed that about 54.1% of AML had at least one type of chromosome change.…”

CD34‐positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform

“…Recent utilization of molecular testing has led to the identification of PML-RAR␣ positive variants with atypical morphology [15,33]. Although expression of CD34 was initially considered uncommon [14], recent studies have shown that CD34 positivity occurs in about 20-30% of newly diagnosed cases [12,[20][21][22]. The significance of CD34 expression in APL is unknown but likely identifies an immature form of APL.…”

“…Until recently, the detection of CD34 in t(15;17) APL was considered infrequent [14]; however, several reports have now shown that expression of CD34 occurs in a significant proportion of newly diagnosed t(15;17) APL patients [12,[20][21][22]. Although CD34 positivity has been associated with a lower rate of complete remission in combined subtypes of acute myeloid leukemia (AML) [23][24][25], the significance of CD34 expression in t(15;17)/ PML-RAR␣ APL is not known.…”

Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study

“…1,2 Progress of diagnostic methods, that is, morphology, cytogenetics, immunophenotyping and molecular biology has led to the identification of prognosis factors [3][4][5] and has helped to better stratify patients. 6 Nevertheless, it is difficult to properly appreciate the efficacy of induction therapy before the first informative examination of bone marrow smears.…”